JP2012180375A - Agent for prevention, amelioration and treatment of dysbolism accompanying with aging - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an agent for prevention, amelioration and treatment of dysbolism developing with aging, and a food and drink having prevention, amelioration and treatment action on dysbolism developing with aging.SOLUTION: The agent for prevention, amelioration and treatment of dysbolism includes a cultured product and/or microbial cell obtained by culturing lactic bacteria belonging to Lactobacillus gasseri as an active component. There is further provided a method for preparing foods and drinks containing the active component and having prevention, amelioration and treatment action on dysbolism.

Description

The present invention relates to a preventive / ameliorating / treating agent for metabolic disorders occurring with aging and / or a food / beverage product having an effect of preventing / ameliorating / treating metabolic disorders occurring with aging.

Aging is an unavoidable life phenomenon for organisms. Various factors have been cited as hypotheses as causes of aging. For example, there are a program theory and an error failure theory at the cell level. Whichever theories are taken, it is unclear how changes caused by the aging mechanism in the cells are related to the aging phenomenon in the whole organism. However, there is also an idea that these changes occur in central cell groups and have a ripple effect in general, and changes that occur in individual cells in the periphery influence each other and reflect them in the aging phenomenon in general. is there. Various indicators have been proposed to use these changes as indicators of the phenomenon of aging, but there is no definite indicator yet.
In recent years, it has been said that by improving various metabolic disorders, metabolic disorders, or dysfunctions that occur with aging, life extension is realized, and various aging indices are lowered.
With the establishment of a Westernized diet, the metabolic abnormalities of Japanese people with aging are changing.

Various diseases that are considered to be caused by metabolic abnormalities that occur with aging, which have been particularly problematic in recent years, include hyperlipidemia due to obesity, senile dementia with brain amyloid accumulation, immune abnormalities,
Intestinal dysfunction, renal dysfunction such as colon cancer and uremia resulting from the change of intestinal microorganisms.
There are various causes of obesity, but no radical treatment has been found that is more effective than diet or exercise. Conventionally, as a body fat accumulation inhibitor with aging other than dietary therapy, a method of administering a fruit or essence of a rose family plant (Patent Document 1), a method of administering a composition derived from buckwheat (Patent Document 2) ), A method of administering procyanidins (Patent Document 3), a method of administering winter pericarp and coconut pericarp (Patent Document 4), a method of changing energy metabolism efficiency by administering a specific fatty acid (Patent Document 5), etc. And agents have been proposed. However, there is no proposal to suppress fat accumulation by Lactobacillus gasseri having intestinal colonization described below in the present invention.
There are two types of senile dementia, cerebrovascular dementia and Alzheimer-type dementia. In particular, the occurrence of Alzheimer-type dementia accompanied by accumulation of amyloid in the brain (amyloidosis) has increased in recent years. As a substance that suppresses amyloid accumulation disease (amyloidosis), a method of administering amyloid β protein (Patent Document 6), a method of administering a fragment of amyloid protein (
Patent Document 7), a method of administering a sugar composition having a specific structure substituted with an anion (Patent Document 8), and the like have been proposed. However, there is no proposal to suppress cerebral amyloid accumulation caused by Lactobacillus gasseri having intestinal colonization described below in the present invention.

The decline in kidney function associated with aging has been attributed to various causes such as a decrease in glomerular function due to aging, a decrease in mesangium cell function, and accumulation of waste products and IgA. Proposed new therapeutic agents and methods, such as a method of administering IGF-1 or IGF-3, a method of administering an IP receptor agonist (Patent Document 9), etc., in order to suppress a decrease in kidney function associated with aging Has been. However, there is no proposal to suppress the decrease in kidney function and metabolism due to Lactobacillus gasseri having intestinal colonization described below in the present invention.
All of the above-mentioned diseases greatly limit the thinking and behavior of the elderly, and as a result, the quality of life (QOL) of the elderly is reduced.
Various therapeutic agents for improving the symptoms of these diseases have been proposed and put into practical use, but do not drastically improve the QOL of the elderly.

JP-A-8-198768 JP 9-183735 A JP-A-9-291039 JP-A-11-164668 JP 2001-286268 A Japanese National Publication No. 6-507585 Japanese National Patent Publication No. 11-500462 Special table 2001-513569 JP 2000-191523 A

The inventors of the present invention have been researching lactic acid bacteria having colonization in the human intestinal tract. A culture obtained by culturing lactic acid bacteria having colonization in the intestinal tract, particularly lactic acid bacteria belonging to Lactobacillus gasseri It has been found that when administered and / or microbial cells, these microorganisms act on the host by colonizing in the intestinal tract, resulting in a significant increase in life span in experimental animals. As a result of further research, Lactobacillus ga
sseri ) is administered to aging animals, the Lactobacillus Lactobacil
lus gasseri ) acts on the host to improve aging-related metabolic abnormalities, suppress kidney function decline and deterioration, improve lipid metabolism that causes obesity, and suppress cerebral amyloid accumulation It was found to have a surprising effect. As a result, it was found that QOL accompanying aging was clearly improved, and the present invention was completed.
Accordingly, an object of the present invention is to provide a culture product obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or a preventive / ameliorating / treating agent for metabolic disorders containing the bacterial cells as active ingredients. And
Furthermore, the present invention provides a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or prevention of metabolic disorders associated with aging by adding the cells.
It is an object to provide a food or drink having an improvement / treatment effect.

The inventors of the present invention have been researching various fermented milks, and among the lactic acid bacteria isolated from these fermented milks and human-derived lactic acid bacteria, Lactobacillu
s gasseri ) has a high intestinal colonization that is not seen in the past, and this Lactobacillus gasseri is associated with aging due to the intestinal colonization that was not known in the past It has been found that it improves metabolic abnormalities and, as a result, suppresses the decline and deterioration of kidney function, reduces the accumulation of lipids that cause obesity, further suppresses the accumulation of amyloid in the brain, and extends the life span. Successfully solved the problem.

The present invention relates to a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or a prophylactic, ameliorating, or therapeutic agent for metabolic disorders associated with aging, which comprises microbial cells as active ingredients.
Moreover, this invention relates to the food-drinks which have the prevention, improvement, and treatment effect | action of the metabolic disorder accompanying aging which added such an active ingredient.
That is, this invention is invention which consists of the following structure described in the claim.

(1) A preventive, ameliorating, or therapeutic agent for metabolic disorders comprising as an active ingredient a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or bacterial cells.
(2) a Lactobacillus gasseri (Lactobacillus gasseri) Lactobacillus lactic acid bacteria belongs with human intestinal fixability gasseri (Lactobacillus gasseri) (1) preventing or ameliorating or therapeutic agent for metabolic disorders described.
(3) The metabolic disorder is renal dysfunction, cerebral amyloidosis, or lipid metabolism disorder (1
) Or (2) a preventive, ameliorating or treating agent for metabolic disorders.
(4) Prevention / amelioration of metabolic disorders according to any one of (1) to (3), wherein the culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri is fermented milk.
Therapeutic agent.
(5) Lactobacillus gasseri Lactobacillus gasseri Lactobacillus gasseri SBT2055 (FERM BP-10953) (1) to (4)
A preventive, ameliorating or treating agent for metabolic disorders as described in any of the above.
(6) A culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or a food or drink having a preventive, ameliorating, or therapeutic effect on metabolic disorders with the addition of bacterial cells.

INDUSTRIAL APPLICABILITY According to the present invention, a preventive / improving / therapeutic agent for metabolic disorders comprising a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or bacterial cells as an active ingredient, and metabolic disorders. A food or drink having a preventive, ameliorating, or therapeutic effect can be provided.
The preventive / ameliorating / treating agent for metabolic disorders provided by the present invention has extremely low toxicity and side effects, and is also useful as a food material.

The life span of experimental animals is shown. A weight gain curve is shown. Shows the number of Bifidobacterium in feces. The number of clostridium in feces is shown. Shows changes in urinary excretion. Shows urinary 8-OHDG excretion. The accumulation amount of amyloid in the brain is shown. The correlation analysis figure of body weight and abdominal wall fat weight is shown. The self-starting movement measurement result of an animal is shown. The measurement result of a blood glucose level is shown. The helper T cell component ratio is shown. Shows pH in the cecum. The fluctuation value of fecal IgA is shown. Shows feed efficiency.

The present invention has been made in order to solve the above-mentioned problems, and the present inventors newly set the following criteria and screened strains that meet the purpose when screening the target lactic acid bacteria. Selected. That is, the present inventors, among fermented milk and many Lactobacillus gasseri derived from humans, are highly resistant to gastric acid, have good growth under low pH conditions, and exhibit high colonization in the human intestinal tract. It has the ability to prevent, improve, and treat various metabolic abnormalities associated with aging by colonizing in the intestinal tract, showing intestinal cell affinity, bile acid resistance, and high survival when applied to food. We set various conditions such as excellent flavor, physical properties, etc., and conducted extensive research on the selection of strains. As a result of screening under these conditions, the following strains could be selected as strains meeting these conditions. This strain is deposited at the Patent Microorganism Depositary, National Institute of Advanced Industrial Science and Technology under the following deposit number.

Strain Lactobacillus gasseri SBT2055 FERM BP-10953
This strain has a high affinity for human intestinal cells, and when orally administered, it can survive and reach the intestinal tract and can be resident in the intestinal tract for a long period of time, and grows in the intestinal tract It acts on the host to prevent, ameliorate, and treat metabolic disorders associated with aging. Lactobacillus gasseri ( Lactobacillus gasseri ), which is administered from outside the body, is established in the intestine and exhibits such a physiological effect, and has been clarified for the first time by the present inventors.

Furthermore, in the present invention, not only the deposited strain but also Lactobacillus gasseri isolated from humans or fermented milk and any of the above-described actions can be used.
Next, the culture method of these lactic acid bacteria is described.
As the Lactobacillus gasseri culture medium of the present invention, various media such as a milk medium or a medium containing milk components, a semi-synthetic medium not containing this, or the like can be used. An example of such a medium is a reduced skim milk medium obtained by reducing skim milk and then heat sterilizing.
The culture method is a static culture or a neutralization culture in which pH is controlled to be constant. However, the culture method is not particularly limited as long as the bacteria grow well.

In the present invention, the culture and / or cells obtained as described above are used as active ingredients. A dried powder may be used as the active ingredient. Such drying is preferably performed by freeze-drying because the cells can be dried without deteriorating the cells.
These active ingredients are preferably taken orally. These powders can be mixed with an appropriate excipient such as lactose and orally administered as a powder, tablet, pill, capsule, granule or the like. The dosage is appropriately determined individually in consideration of the symptom, age, etc. of the administration subject, but is usually 0.5 to 10 g as a dry product per day for an adult, and this may be divided into several times a day. Particularly preferably, 10 ⁸ to 10 ¹² cfu per adult, with each strain as a viable cell
/ Day, it is possible to exert the intended effect of the present invention. By taking in this way, it settles in the intestinal tract and exhibits the desired effect.

Moreover, you may add the active ingredient of this invention to a raw material during the manufacturing process of food-drinks. As the food and drink, any food and drink may be used. Examples thereof include milk drinks, fermented milk, fruit juice drinks, jelly, candy, dairy products, processed eggs such as mayonnaise, and foods such as butter cakes and other confectionery breads. be able to. However, as a characteristic of the present invention, it is necessary to settle in the intestinal tract while the lactic acid bacteria are alive, and it is preferable to avoid excessive heating. In addition, conventional techniques such as microcapsules may be employed to take measures to avoid heating.
Furthermore, the food and drink in the present invention is the aforementioned Lactobacillus gasseri ( Lactobacil
It may be yogurt produced by lactic acid fermentation using a strain of lus gasseri ).
Lactobacillus gasser ( Lactobacillus gasser) as a lactic acid strain used in the present invention
i ) Test examples using SBT2055 (LG2055) will be shown, and the bacteriological properties and in vitro and in vivo effects will be specifically described. However, the present invention is not limited to this description.
[Test example]

Properties of LG2055 stock Mycological properties (1) Fungal form
The result after anaerobic culture at 37 ° C. for 48 hours using LBS agar plate medium is shown.
Shape: Aspergillus Size: 0.5-1 × 3-4μm
Many linked (2) Gram stain positive (3) Colony shape Shape: Circular Perimeter: Wave Size: Diameter 2-3mm
Color: White Surface: Smooth (4) Spore formation Negative (5) Gas production None (6) Motility None (7) Catalase activity Negative (8) Nonfat milk coagulability Coagulation (9) Gelatin liquefaction None (10) Nitrate reduction None (11) Indole productivity None (12) Hydrogen sulfide productivity None

2. Fermentability of sugars The results of examining the fermentability of sugars with commercially available bacteria identification kits (Api 50CH, Biomeryu) and others are described below.
Glycerol −
Erythritol −
D-arabinose −
L-arabinose +
Ribose −
D-xylose-
L-xylose-
Aditol-
β-methyl-D-xyloside −
Galactose +
D-glucose +
L-Fructose +
D-Mannose +
L-sorbose −
Rhamnose −
Dulcitol −
Inositol −
Mannitol −
Sorbitol −
α-methyl-D-mannoside −
α-methyl-D-glucoside −
N-acetyl-glucosamine +
Amygdalin +
Arbutin +
Esclin +
Salicin +
Cellobiose +
Maltose +
Lactose +
Melibiose −
Sucrose +
Trehalose +
Inulin −
Merezitose −
D-Raffinose −
Amidon −
Glycogen −
Xylitol −
β-gentiobiose +
D-Tulanose −
D-lyxose −
D-Tagatose +
D-arabitol −
L-arabitol −
Gluconate −
2-Kethogluconate −
5-ketotogluconate −
(+ Indicates that there is fermentability, − indicates that there is no fermentability.)

The taxonomic properties and sugar fermentability indicated the properties of a typical Lactobacillus acidophilus complex.

LG2055株のDNA同士の相同性を100％、LG2055株と大腸菌とのDNA相同性を０％としたと
きの、LG2055株と各基準株のDNA相同性をDNAハイブリダイゼーション法により検討した。
その結果、LG2055株はラクトバチルス・ガセリJCM1131株と90％以上の相同性を有してい
たため、LG2055株はラクトバチルス・ガセリと同定された。 Subsequently, the confirmation test by a DNA homology test was implemented as follows.
DNA homology test The DNA of Escherichia coli was extracted and purified as a reference strain of Lactobacillus described below, the test strain LG2055, and as a control.

DNA homology between the LG2055 strain and each of the reference strains was examined by DNA hybridization when the homology between the DNAs of the LG2055 strain was 100% and the DNA homology between the LG2055 strain and E. coli was 0%.
As a result, since the LG2055 strain had 90% or more homology with the Lactobacillus gasseri JCM1131 strain, the LG2055 strain was identified as Lactobacillus gasseri.

Gastric acid resistance In the gastric acid resistance test, an artificial gastric fluid having a pH of 2.0 was prepared according to the method of Higuchi et al. (Intestinal Bacteriology Journal 14.11-18.2000), and a gastric acid resistance test was conducted. The LG2055 strain survived for 3 hours or more.

Artificial intestinal juice resistance Artificial intestinal fluid containing bile powder was prepared according to the method of Higuchi et al. (Intestinal Bacteriology Journal 14.11-18.2000), and the resistance was tested by adding LG2055 strain that had been treated with artificial gastric juice to this. , Showed viability of more than 20 hours. The LG2055 strain was confirmed to pass through the gastrointestinal tract and survive to reach the large intestine.

Human intestinal transit ability and intestinal colonization 42 healthy adult volunteers with fermented milk fermented with 39% non-fat milk solid 9.5%, milk fat 3.0% fermented milk fermented at 39 degrees for 4 hours For 4 weeks, 100 g was eaten once a day, and changes in the intestinal bacteria were observed. During the test period, evaluation was performed by eating freely except forbidding foods, oligosaccharides, and drugs that affect enterobacteria. The LG2055 strain, which was not detected before the test, was detected in all subjects after 4 weeks, indicating that both strains have high intestinal colonization.

Animal test A. Effect test on the life span of experimental animals in vivo Preparation of lactic acid bacteria skim milk culture
LG2055 strain was used. Lactic acid bacteria were cultured at 37 ° C. for 16 hours in a 11.55% skim milk medium supplemented with 0.5% yeast extract (manufactured by Asahi Beer Foods) sterilized at 115 ° C. for 20 minutes. The obtained culture was freeze-dried and then ground in a mortar.

2. Preparation of test feed Table 1 shows the diet composition based on AIN-93M (Oriental Yeast Co., Ltd.). To this feed, 5% skim milk or the above skim milk lactic acid bacteria culture was added.

3. Test animal Senescence-Accelerated Mouse (SAM) P8 female mouse, a 5-week-old aging promotion model (
2 groups, each group 30). After pre-breeding for 1 week in AIN-93M, the breeding was continued until the above test feed died. During this time, ion-exchanged water and feed (within 7 to 8 g) were ad libitum.

4). Body weight measurement The body weight was measured once a week during the breeding period. Analysis of variance was performed for the body weight from the age of 5 to 60 weeks of age by the division method.

5. Dietary intake measurement method Dietary intake was measured about once every 4 weeks. A pre-weighed feed was given, and the remaining amount of food in the container was measured at the same time zone the next day, and the amount of food intake per day was calculated.

6). Flora analysis Fresh stool was collected, and 5 weeks old (initial value), 3 months old, 5 months in accordance with the method of Mitsuoka et al. Intestinal flora analysis was performed at age 7, 7 months, 10 months, and 12 months. About the obtained data, analysis of variance by the division method was performed.

B. Test on effects on aging index (biological function at 40 weeks of age)
1. Preparation of lactic acid bacteria skim milk culture LG2055 strain was used in the same manner as A described above. Lactic acid bacteria were cultured at 37 ° C. for 16 hours in a 11.55% skim milk medium supplemented with 0.5% yeast extract (manufactured by Asahi Beer Foods) sterilized at 115 ° C. for 20 minutes. The obtained culture was freeze-dried and then ground in a mortar.

2. Test feed As described above, a diet based on AIN-93M (manufactured by Oriental Yeast Co., Ltd.) was prepared, and 5% skim milk or the above skim milk lactic acid bacteria culture was added to this feed.

3. Experimental animals Five-week-old SAM P8 female mice (obtained from Japan SLC) were used as 2 groups, 10 mice each. AIN
After pre-breeding at -93M for 1 week, the above-mentioned test feed was raised for 36 weeks. During this time, ion-exchanged water and feed were ingested freely. After raising to 40 weeks of age, the animals were fasted for about 16 hours, opened under anesthesia with Nembutal (Dainippon Pharmaceutical Co., Ltd.), and sacrificed by inferior vena cava blood sampling.

4). Body weight measurement The body weight was measured once a week during the breeding period. About the obtained data, analysis of variance by the division method was performed.

5. Dietary intake measurement method Dietary intake was measured at a rate of once a week (after 1 week) every week when young. A pre-weighed feed was given, and the remaining amount of food in the container was measured at the same time zone the next day, and the amount of food intake per day was calculated.

6). Metabolic cages During the breeding period, the animals were raised four times in a metabolic cage, and urine collection and feces were collected. Rearing in metabolic cages was carried out at 14, 22, 29 and 38 weeks of age. After two days of breeding, feces and urine were collected for approximately 24 hours from the 3rd to 4th day. Drinking water, feed intake and body weight were also monitored during the period.

7). Measurement of urinary 8-hydroxydeoxyguanosine The urine obtained in metabolic cage breeding was measured using an ELISA kit for 8-OHDG measurement (manufactured by Japan Aging Control Laboratory).

8). Measurement of amyloid accumulation in the brain Dissection was performed immediately after sacrifice and the cerebrum was removed. The obtained cerebrum was homogenized with a Teflon (registered trademark) homogenizer using PBS containing 0.5% protein inhibitor mixture (manufactured by SIGMA), and using an amyloid beta (1-42) measurement kit (manufactured by Immunobiological Research Institute). It was measured.

9. The weight of the abdominal wall fat was dissected immediately after slaughtering, and the left and right abdominal wall fats were excised respectively, and the weight was measured with a precision balance METTLER AE240 (manufactured by Siebel Hegner Japan).

10. Standing and spontaneous movement measurement method
At 40 weeks of age, spontaneous movements and standing movements of mice were measured. The number of movements between coils in 30 minutes and the number of standing were measured. For the measurement, an experimental animal momentum measuring device (Muromachi Kikai Co., Ltd.) was used.

11. Plasma analysis After fasting for about 16 hours, the whole blood was collected from the inferior vena cava under Nembutal anesthesia, and after anticoagulant treatment (heparin 10 units / ml), plasma was obtained by centrifugation. Then biochemical automatic analyzer
It measured using FDC5500 (made by Fuji Film Medical Co., Ltd.).

12 Measurement of fecal IgA Feces obtained from metabolic cages were dried with a centrifugal evaporator CVE-200D (EYELA), weighed, and PBS containing 0.5% protein inhibitor (SIGMA) was added.
The feces were dispersed at a concentration of 0.05 g / ml and homogenized with a homogenizer (manufactured by Ikemoto Rika Kogyo Co., Ltd.). This dispersion was centrifuged at 4 ° C. and 15,000 rpm for 10 minutes, and the supernatant was subjected to mouse IgA measurement. Measurement was performed using an ELISA kit for mouse IgA measurement (manufactured by BETHYL).

13. Blood cell analysis After mice were fasted for about 16 hours, a whole blood sample was collected from the inferior vena cava using an anticoagulant-treated (heparin 10 units / ml) syringe under Nembutal anesthesia, and then a fully automatic hemocytometer MEK-6158 ( Nihon Kohden Co., Ltd.).

14 Measurement of Th1 / Th2 cell ratio After removing the spleen, it is crushed aseptically, and a spleen cell suspension is prepared while adding 25 mM HEPES-RPMI. This spleen cell suspension was made into a single cell suspension through a cell strainer according to a conventional method. According to the method of EPICS Application Note 8, cell surface CD3 of spleen lymphocytes, intracellular IL
4. Intracellular INF-gamma was fluorescently stained. After this, we analyze with Coulter EPICS XL,
CD3 positive cell ratio and Th1 / Th2 cell ratio were calculated.

Test results A. Test results on effects on the life span of experimental animals in vivo FIG. 1 shows the life span of mice used in the experiment. Compared to control, fermented milk of the present invention (LG20
55) It was revealed that the administration group had an effect on life extension.
In addition, when the weight gain curves were compared (FIG. 2), no significant difference was observed.

B. Test results on effects on aging index Table 2 shows the analysis results of changes in intestinal flora up to 12 months of age. The fermented milk (LG2055) administration group of the present invention showed a significant increase in fecal Bifidobacterium and a significant decrease in lecithinase-negative Clostridium. Time-dependent changes were observed in both fungal groups.

In the fermented milk (LG2055) administration group of the present invention, it became clear that the number of Bifidobacterium spp. Increased with the age of life (FIG. 3). On the other hand, it was confirmed that the number of Clostridium bacteria significantly decreased in the fermented milk (LG2055) administration group of the present invention (FIG. 4).

FIG. 5 shows the analysis results of the urinary excretion observed throughout the experimental period. Fermented milk of the present invention (
In the LG2055 strain) administration group, urine excretion increased.

FIG. 6 shows the excretion amount of the oxidation marker (8-OHDG) excreted in urine. Although excretion was active in both groups during the period of high metabolism, it was revealed that the excretion amount of the fermented milk (LG2055 strain) administration group of the present invention was high throughout the entire test period.
From the above measurement results of urinary excretion and 8-OHDG excretion, it was revealed that the fermented milk of the present invention (containing LG2055 strain) prevents / improves the decrease in kidney function with aging.

FIG. 7 shows the measurement results of the cerebral amyloid accumulation amount. In the fermented milk (LG2055 strain) administration group of the present invention, inhibition of amyloid accumulation accompanying aging was confirmed, and the prevention / amelioration effect of amyloidosis could be confirmed.
In addition, the prevention / improvement effect of dementia was confirmed together with the results of the standing exercise test shown below.

FIG. 8 shows a comparison result of the abdominal wall fat accumulation amount. In the fermented milk (LG2055 strain) administration group of the present invention, it was confirmed that it decreased significantly, and it became clear that lipid metabolism abnormality accompanying aging was improved.

FIG. 9 shows the observation result of the spontaneous movement of the mouse. Abnormal movements were observed in the control group, and there were few such abnormal behaviors in the fermented milk (LG2055 strain) administration group of the present invention. It was found that fermented milk of the present invention (containing LG2055 strain) reduced amyloid accumulation in the brain and was effective in suppressing dementia associated with aging.

FIG. 10 shows the blood glucose level measurement results. By the fermented milk (LG2055 strain) administration group of the present invention, the occurrence of hyperglycemia accompanying aging could be suppressed.

FIG. 11 shows the analysis result of the spleen helper T cell repertoire. Fermented milk of the present invention (LG20
In the (strain 55) administration group, it was confirmed that cellular immune function was activated. At the same time, it was confirmed that the ratio of CD3-positive cells (T cells) in the spleen was also increased.

FIG. 12 shows the cecal content pH measurement results. It was confirmed that the fermented milk of the present invention (LG2055 administration group) lowered the intestinal pH and improved intestinal metabolism.

FIG. 13 shows the excretion amount of fecal IgA. The excretion amount of fecal IgA is the fermented milk of the present invention (LG2055 strain)
It was suppressed in the administration group.

FIG. 14 shows the feed efficiency throughout the test period. It was confirmed that the feed efficiency throughout the test period was significantly higher in the fermented milk (LG2055 strain) administration group of the present invention. On the other hand, it was found from FIG. 14 that the negative effect on feed efficiency due to aging was suppressed. This result proves that “we live well and become chubby”, and we were able to confirm the effect of maintaining and improving QOL.

1. Dry powder
The LG2055 strain was cultured in a 10% reduced skim milk medium (heated at 121 ° C. for 10 minutes), and this culture was freeze-dried and powdered to prepare the preventive / ameliorating therapeutic agent of the present invention (A).

2. Fermented milk
LG2055 strain was cultured in MRS liquid medium. Each culture solution in the logarithmic growth phase was inoculated with 1% in 10% reduced skim milk (115 ° C., sterilized for 20 minutes) supplemented with 0.35% yeast extract to prepare individual mother cultures.
This was prepared by adding 2.5% each to yogurt mix (10% reduced skim milk was added and heated at 100 ° C. for 10 minutes). Fermentation was performed at 37 ° C., and when the lactic acid acidity reached 0.85, the mixture was cooled, the fermentation was terminated, and fermented milk having the preventive improvement therapeutic action of the present invention was prepared (B).

3. Formulation Example 1
Cells in the logarithmic growth phase were centrifuged at 4 ° C. and 7,000 rpm for 15 minutes from a liquid culture of the LG2055 strain, washed with sterilized water, and this was repeated three times to obtain washed cells. This was freeze-dried to obtain cell powder. 4 parts of skimmed milk was mixed with 1 part of this bacterial cell powder, and 1 g of this powder was tableted by a conventional method with a tableting machine to prepare a tablet containing 200 mg of bacterial cell. Also, LG205 above
Fermented milk containing 5 strains was freeze-dried and directly compressed using the resulting powder.

4). Encapsulating agent After freeze-dried powder was powdered, it was granulated by granulation, and 10 mg each was filled into empty capsules to form capsules.

5. Formulation Example 2
The LG2055 strain was inoculated into 5 L of MRS liquid medium (Difco), followed by static culture at 37 ° C. for 18 hours.
After inoculating the LG2055 strain in 5 L of skim milk, static culture was performed at 37 ° C. for 18 hours. 7,000rpm after completion of culture
For 15 minutes to obtain 1/50 volume of each concentrated bacterial cell of the culture solution. Next, the concentrated cells are mixed in the same amount with a dispersion medium containing 10% by weight of skim milk powder and 1% by weight of sodium glutamate,
After adjusting to pH 7, lyophilization was performed. The obtained freeze-dried product was sized with a 60-mesh sieve to obtain a freeze-dried bacterial powder.
In accordance with the provisions of the 13th revised Japanese Pharmacopoeia General Rules for Preparations, “Powder”, add 1 g of freeze-dried bacteria obtained in 5 above to 400 g of lactose (Japan Pharmacopoeia) and 600 g of potato starch (Japan Pharmacopoeia) to evenly Mixed to produce a powder.

6). Formulation Example 3
Tablets were produced with the following formulation.
(1) 50 g freeze-dried culture of LG2055 strain nonfat dry milk medium,
(2) 90 g lactose,
(3) Corn starch 29g,
(4) Magnesium stearate 1 g,
This mixture is compressed by a compression tablet machine, and tablets 100 mg containing 40 mg of active ingredient per tablet
Pieces were manufactured.

7). Formulation Example 4
The LG2055 strain was cultured in whey medium (0.5% yeast extract and 0.1% trypticase peptone added), and the cells were collected by centrifugation. 1 g of this culture was mixed with 5 g of lactose and formed into granules to obtain granules.

8). Food (1) Beverage Containing LG2055 The freeze-dried powder of the washed cells was mixed with 200 ml of milk so that each of the LG2055 strains contained 10 ⁸ or more to obtain a beverage containing the preventive / ameliorating treatment agent of the present invention. It had a good flavor.
(2) Fermented milk
LG2055 strain yogurt mix (2% skim milk was added to raw milk and heated at 100 ° C for 10 minutes)
And inoculated at 20 ° C. for 24 hours. In a product made into yogurt after filling into a paper cup and cooling
The viable cell count concentration of LG2055 strain was 10 ⁸ or more per 100 g.

(3) Fermented butter Fermented butter (wt / wt)
Milk fat 96.8%
Salt 1.2
1. Sample (A) obtained in 2

(4) Butter cake Butter cake (wt / wt)
Butter 24%
Light flour 24
Sugar 24
Whole egg 24
2. Sample (B) obtained in 4
Fragrance a little

(5) Mayonnaise Mayonnaise (wt / wt)
Salad oil 65%
Egg yolk 17
Vinegar 10
1. Sample (A) obtained in 3
Spice 4.4
Monosodium glutamate 0.6

Claims (3)

  A fat accumulation-reducing agent comprising a culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri and / or bacterial cells as an active ingredient.   The fat accumulation-reducing agent according to claim 1, wherein the culture obtained by culturing lactic acid bacteria belonging to Lactobacillus gasseri is fermented milk. Lactic acid bacteria belonging to Lactobacillus gasseri (Lactobacillus gasseri)
The fat accumulation-reducing agent according to claim 1 or 2, which is gasseri (Lactobacillus gasseri) SBT2055 (hereinafter referred to as LG2055) (FERM BP-10953).

Images